Sexually diergic hypothalamic-pituitary-adrenal axis responses to selective and non-selective muscarinic antagonists prior to cholinergic stimulation by physostigmine in rats
- PMID: 29122691
- PMCID: PMC5835407
- DOI: 10.1016/j.brainresbull.2017.11.002
Sexually diergic hypothalamic-pituitary-adrenal axis responses to selective and non-selective muscarinic antagonists prior to cholinergic stimulation by physostigmine in rats
Abstract
Central cholinergic systems regulate the hypothalamic-pituitary-adrenal (HPA) axis differentially in males and females (sexual diergism). We previously investigated the role of muscarinic receptors in this regulation by administering physostigmine (PHYSO), an acetylcholinesterase inhibitor, to male and female rats pretreated with scopolamine (SCOP), a nonselective muscarinic antagonist. SCOP pretreatment enhanced adrenocorticotropic hormone (ACTH) and corticosterone (CORT) responses in both sexes, but males had greater ACTH responses while females had greater CORT responses. In the present study, we further explored the role of muscarinic receptor subtypes in HPA axis regulation by administering PHYSO to male and female rats following SCOP or various doses of either the M1 or the M2 selective muscarinic receptor antagonists, pirenzepine (PIREN) or methoctramine (METHO). Blood was sampled before and at multiple times after PHYSO. ACTH and CORT were determined by highly specific immunoassays. M1 antagonism by PIREN prior to PHYSO resulted in sustained, dose-dependent increases in ACTH and CORT: ACTH responses were similar in both sexes, and CORT responses were greater in females. M2 antagonism by METHO prior to PHYSO resulted in overall decreases in ACTH and CORT: ACTH and CORT responses were higher in females but lower in both sexes than the hormone responses following PIREN or SCOP pretreatment. Area under the curve analyses supported these findings. These results suggest that specific muscarinic receptor subtypes differentially influence the HPA axis in a sexually diergic manner.
Keywords: Cholinergic; Methoctramine; Muscarinic; Pirenzepine; Scopolamine; Sexual diergism.
Copyright © 2017 Elsevier Inc. All rights reserved.
Conflict of interest statement
None.
Figures








References
-
- Abrams P, Andersson K-EE, Buccafusco JJ, Chapple C, Groat WC, de Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565–78. - PMC - PubMed
-
- Aramakis VB, Bandrowski AE, Ashe JH. Role of muscarinic receptors, G-proteins, and intracellular messengers in muscarinic modulation of NMDA receptor-mediated synaptic transmission. Synapse. 1999;32:262–75. - PubMed
-
- Assenmacher I, Szafarczyk A, Alonso G, Ixart G, Barbanel G. Physiology of neural pathways affecting CRH secretion. Ann N Y Acad Sci. 1987;512:149–61. - PubMed
-
- Aura J, Sirviö J, Riekkinen P. Methoctramine moderately improves memory but pirenzepine disrupts performance in delayed non-matching to position test. Eur J Pharmacol. 1997;333:129–34. - PubMed
-
- Avissar S, Egozi Y, Sokolovsky M. Studies on muscarinic receptors in mouse and rat hypothalamus: a comparison of sex and cyclical differences. Neuroendocrinology. 1981a;32:295–302. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources